在胰腺癌中,FNDC4驱动转移和免疫逃避
Jingwei Li1, Renfei Wu2, Xiaohan Jin1
1Shanghai Jiao Tong University, Shanghai, Shanghai, China.
Cancer research
|October 9, 2025
概括
含有4 (FNDC4) 的III类纤维素域驱动胰腺癌的进展和转移,通过促进免疫逃避和维持关键信号通路. 抑制FNDC4可以减少瘤生长,增强抗瘤免疫力,从而成为潜在的治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 胰腺管腺癌 (PDAC) 是一种高度转移的癌症,治疗选择有限.
- 确定PDAC进展的分子驱动因素对于开发向疗法至关重要.
研究的目的:
- 为了研究纤维龙菌素III型含有4 (FNDC4) 域在PDAC进展中的作用.
- 探索FNDC4作为PDAC的潜在治疗点.
主要方法:
- 在PDAC模型中FNDC4敲击.
- 分析FNDC4对瘤生长,转移和免疫细胞透的影响.
- 调查FNDC4的分子机制,包括信号通路和下游效应器.
- 使用FNDC4抑制的组合疗法研究.
主要成果:
- 在转移的PDAC中,FNDC4的水平升高,与不良结果相关.
- 降低FNDC4可以减少瘤生长和转移.
- FNDC4通过诱导M2巨细胞两极化来促进免疫逃避.
- 抑制FNDC4可以增强T细胞透和抗瘤免疫力.
- 与其他疗法相结合的FNDC4抑制可以改善瘤控制.
结论:
- FNDC4是PDAC进展,转移和免疫逃避的关键驱动因素.
- 向FNDC4代表了对PDAC治疗的有希望的战略.
- 涉及FNDC4抑制的组合疗法显示提高了疗效.
相关概念视频
01:35Cancer Cell Migration through Invadopodia
3.2K
Invadosome is a broad category of cell surface structures with proteolytic activity that degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
3.2K
02:30Metastasis
6.4K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.4K